A novel angiogenesis inhibitor, Ki23057, is useful for preventing the progression of colon cancer and the spreading of cancer cells to the liver

European Journal of Cancer

Volumn 43, Issue 17, 2007, Pages 2612-2620

  Sakurai, Katsunobu ^a   Yamada, Nobuya ^a   Yashiro, Masakazu ^a   Matsuzaki, Taro ^a   Komatsu, Midori ^a   Ohira, Masaichi ^a   Miwa, Atsushi ^b   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KIRIN BREWERY CO LTD   (Japan)

Author keywords

Angionenesis inhibitor; Colon cancer therapy; Molecular target therapy; VEGFR2 autophosphorylation inhibitor

Indexed keywords

ANGIOGENESIS INHIBITOR; KI 23057; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; DRUG STRUCTURE; HUMAN; HUMAN CELL; LIVER METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR VOLUME; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; ENDOTHELIAL CELLS; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; QUINOLINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 36049046092     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.09.002     Document Type: Article

References (28)

1. Nakamura K., Yamamoto A., Kamishohara M., et al. KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth. Mol Cancer Ther 3 (2004) 1639-1649
2. Wedge S.R., Ogilvie D.J., Dukes M., et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62 (2002) 4645-4655
3. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337
4. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2 (1996) 561-566
5. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 (2002) 472-480
6. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
7. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3 (2003) 401-410
8. Guba M., Seeliger H., Kleespies A., Jauch K.W., and Bruns C. Vascular endothelial growth factor in colorectal cancer. Int J Colorectal Dis 19 (2004) 510-517
9. Takahashi Y., Kitadai Y., Bucana C.D., Cleary K.R., and Ellis L.M. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55 (1995) 3964-3968
10. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
11. Veikkola T., Karkkainen M., Claesson-Welsh L., and Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 60 (2000) 203-212
12. Takahashi T., Yamaguchi S., Chida K., and Shibuya M. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. Embo J 20 (2001) 2768-2778
13. Rosen L.S. VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist 10 (2005) 382-391
14. Kang S.M., Maeda K., Onoda N., et al. Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis. Int J Cancer 74 (1997) 502-507
15. Werther K., Christensen I.J., Brunner N., and Nielsen H.J. Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group. Eur J Surg Oncol 26 (2000) 657-662
16. Shimizu T., Fujiwara Y., Osawa T., et al. Orally active anti-proliferation agents: novel diphenylamine derivatives as FGF-R2 autophosphorylation inhibitors. Bioorg Med Chem Lett 14 (2004) 875-879
17. Yamada N., Chung Y.S., Takatsuka S., et al. Increased sialyl Lewis A expression and fucosyltransferase activity with acquisition of a high metastatic capacity in a colon cancer cell line. Br J Cancer 76 (1997) 582-587
18. Nakamura K., Yashiro M., Matsuoka T., et al. A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer. Gastroenterology 131 (2006) 1530-1541
19. Takatsuka S., Yamada N., Sawada T., et al. Contribution of angiogenesis to the progression of colon cancer: possible inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and hepatic metastasis. Int J Oncol 17 (2000) 253-258
20. Hennequin L.F., Stokes E.S., Thomas A.P., et al. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem 45 (2002) 1300-1312
21. Strumberg D., Richly H., Hilger R.A., et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23 (2005) 965-972
22. Traxler P., Allegrini P.R., Brandt R., et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 64 (2004) 4931-4941
23. Drevs J., Zirrgiebel U., Schmidt-Gersbach C.I., et al. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 16 (2005) 558-565
24. Kabbinavar F.F., Hambleton J., Mass R.D., Hurwitz H.I., Bergsland E., and Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23 (2005) 3706-3712
25. Emmanouilides C., Sfakiotaki G., Androulakis N., et al. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer 7 (2007) 91
26. Malet-Martino M., and Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 7 (2002) 288-323
27. Johnston P.G., and Kaye S. Capecitabine: a novel agent for the treatment of solid tumors. Anticancer Drugs 12 (2001) 639-646
28. Nakazawa K., Yashiro M., and Hirakawa K. Keratinocyte growth factor produced by gastric fibroblasts specifically stimulates proliferation of cancer cells from scirrhous gastric carcinoma. Cancer Res 63 (2003) 8848-8852